Author(s): Carvalho, Agostinho Albérico Rodrigues ; Oliveira, Cláudio Duarte ; Gonçalves, Samuel M. ; Campos Jr., António ; Lacerda, João F. ; Cunha, Cristina
Date: 2017
Persistent ID: https://hdl.handle.net/1822/48553
Origin: RepositóriUM - Universidade do Minho
Subject(s): Fungal disease; Vaccination; Aspergillus; Candida; Immunotherapy; Personalized medicine
Purpose of review The remarkable advances in modern medicine have paradoxically resulted in a rapidly expanding population of immunocompromised patients displaying extreme susceptibility to life-threatening fungal infections. There are currently no licensed vaccines, and the prophylaxis and therapy of fungal infections in at-risk individuals remains challenging, contributing to undesirable mortality and morbidity rates. The design of successful antifungal preventive approaches has been hampered by an insufficient understanding of the dynamics of the host-fungus interaction and the mechanisms that underlie heterogenous immune responses to vaccines and immunotherapy. Recent findings Recent advances in proteomics and glycomics have contributed to the identification of candidate antigens for use in subunit vaccines, novel adjuvants, and delivery systems to boost the efficacy of protective vaccination responses that are becoming available, and several targets are being exploited in immunotherapeutic approaches. Summary We review some of the emerging concepts as well as the inherent challenges to the development of fungal vaccines and immunotherapies to protect at-risk individuals.
